LH
PDLI

Lebenthal Holdings’s PDL BioPharma, Inc. PDLI Stock Holding History

Lebenthal Holdings’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-59,216
Closed -$457K – 342
2014
Q4 		$457K Buy
+59,216
New +$469K 0.2% 129

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Lebenthal Holdings's PDLI Position: Q1 2015 in Review

Lebenthal Holdings sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 59,216 shares — an estimated $457K sold.

Lebenthal Holdings first reported a position in PDLI in Q4 2014 and held it in 1 quarter. The position peaked at $457K in Q4 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

  • Lebenthal Holdings reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
  • Lebenthal Holdings sold 59,216 PDL BioPharma, Inc. shares in Q1 2015, an estimated $457K.
  • Lebenthal Holdings first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 1 quarter.
  • Lebenthal Holdings's PDL BioPharma, Inc. position peaked at $457K in Q4 2014.
  • 215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on Lebenthal Holdings's 13F filing for Q1 2015, filed 13 May 2015.